Labiotech.eu

News and Trends 25 Jul 2022

Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization

The Committee for Medical Products for Human Use (CHMP) has recommended the European Commission (EC) make a marketing authorization under exceptional circumstances for a drug to treat a rare condition characterized by brain dysfunction. The drug is called NULIBRY (fosdenopterin) for injection therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. […]

July 25, 2022 - 4 minutesmins - By Liza Laws

News and Trends 25 Jul 2022

Bavarian Nordic gets European monkeypox approval for smallpox vaccine

Danish company Bavarian Nordic A/S says the European Commission (EC) has extended the marketing authorization for the company’s smallpox vaccine, IMVANEX, to include protection from monkeypox and disease caused by vaccinia virus. The approval, which follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) on July 22, 2022, is valid […]

July 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Jul 2022

Drug for acute treatment of social anxiety disorder did not meet primary endpoint

A nasal spray to treat anxiety did not meet its primary endpoint and was not significantly better than the placebo given during a phase 3 clinical trial. Vistagen Therapeutics Inc’s drug, PH94B, was designed to treat people living with anxiety, depression and other central nervous system (CNS) disorders announced the topline results on Friday (July […]

July 25, 2022 - 4 minutesmins - By Liza Laws

News and Trends 25 Jul 2022

NEOsphere Biotechnologies closes financing round

NEOsphere Biotechnologies GmbH has completed a series A financing round to expand its proteomics platform, which screens extensive small-molecule libraries for degraders of pathogenic proteins previously considered undruggable. The funding amount was not disclosed, however, the company told us there were four investors, with the main amount coming from Munich-based Ventura BioMed Investors GmbH. NEOSphere […]

July 25, 2022 - 3 minutesmins - By Jim Cornall

Daniel Baptista-Hon Faculty of Medicine M.U.S.T. Macao

News and Trends 25 Jul 2022

Macao university research finds mRNA vaccine booster offers more protection against Omicron variants

A study in Macao has found people taking the BioNTech mRNA vaccine as the third booster dose produce more neutralizing antibodies against Omicron variants. The study, led by Daniel Baptista-Hon, assistant professor at the Faculty of Medicine at the Macau University of Science and Technology (M.U.S.T.), and Ligong Lu, director of Zhuhai People’s Hospital, was […]

July 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Jul 2022

Replay launches with $55M to reprogram biology by writing and delivering big DNA

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, has launched with $55 million in seed financing. The round was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial. Replay, which is based in San Diego, Cal., and London, U.K., […]

July 25, 2022 - 3 minutesmins - By Jim Cornall

sano genetics trial recruitment precision medicine

Opinion 25 Jul 2022

How to improve patient recruitment in your precision medicine research

Precision medicine research relies on genetic testing at scale, but has long suffered recruitment and retention headaches. The answer, says Patrick Short, CEO of Sano Genetics, is to start early and engage participants deeply. I witnessed first-hand the power of national scale genomics research through my PhD work analyzing genome sequence data from more than […]

July 25, 2022 - 7 minutesmins - By External Contributor

lupus autoimmune disease neutrophil citryll

News and Trends 22 Jul 2022

Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis

British Columbia-based Aurinia Pharmaceuticals Inc. announced today (July 22) that its voclosporin drug has been recommended for marketing authorization to treat adults with active lupus nephritis (LN). The Canadian biopharma company said it is committed to delivering therapeutics that change the course of autoimmune disease after the Committee for Medicinal Products for Human Use (CHMP) […]

July 22, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed

London-based Freeline Therapeutics Holdings plc has just announced that positive data on treating haemophilia has been published by the New England Journal of Medicine (NEJM). This expands upon previous data for up to three-and-a-half years from the phase 1/2 dose-finding B-AMAZE of the company’s AAVS3 gene therapy candidate, FLT180a for people with the debilitating, hereditary […]

July 22, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

InterVenn expands globally to drive the potential of glycoproteomics to improve patient outcomes

Intervenn Biosciences is expanding across Asia-Pacific and North America and opening new facilities in Kuala Lumpur, the Philippines, Australia and California. The company leverages glycoporteomics and says it is adding a large footprint of laboratories and office space for scaling up Intervenn’s software development, technical support, clinical research and business development. Biomedical hubs Aldo Carrascoso, […]

July 22, 2022 - 2 minutesmins - By Liza Laws

In Depth 22 Jul 2022

The coming of age story of RNAi technology

The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two decades of scientific effort, multiple devastating clinical trial setbacks, and billions of dollars spent on research and development, RNAi therapies are finally establishing themselves in […]

July 22, 2022 - 7 minutesmins - By Farhan Mitha

News and Trends 22 Jul 2022

Australia looks to biotech alliance

The Australian government’s Defence department has announced the launch of the Safeguarding Australia through Biotechnology Response and Engagement alliance (SABRE) at the inaugural Australian Defence Science Technology and Research Summit (ADSTAR) The department said SABRE offers opportunities by bringing together different perspectives of biotech from Australia’s universities, research institutes and small medium enterprises (SME) and […]

July 22, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization

Bavarian Nordic gets European monkeypox approval for smallpox vaccine

Drug for acute treatment of social anxiety disorder did not meet primary endpoint

NEOsphere Biotechnologies closes financing round

Macao university research finds mRNA vaccine booster offers more protection against Omicron variants

Replay launches with $55M to reprogram biology by writing and delivering big DNA

How to improve patient recruitment in your precision medicine research

Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis

People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed

InterVenn expands globally to drive the potential of glycoproteomics to improve patient outcomes

The coming of age story of RNAi technology

Australia looks to biotech alliance

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!